These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36902656)

  • 1. Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program.
    Chao TF; Unverdorben M; Kirchhof P; Koretsune Y; Yamashita T; Crozier RA; Pecen L; Chen C; Borrow AP; De Caterina R
    J Clin Med; 2023 Feb; 12(5):. PubMed ID: 36902656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program.
    Chao TF; Hong KS; Lee BC; De Caterina R; Kirchhof P; Reimitz PE; Chen C; Unverdorben M; Wang CC
    J Chin Med Assoc; 2021 May; 84(5):485-490. PubMed ID: 33742992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants.
    Camm AJ; Cools F; Virdone S; Bassand JP; Fitzmaurice DA; Arthur Fox KA; Goldhaber SZ; Goto S; Haas S; Mantovani LG; Kayani G; Grierson Turpie AG; Antoon Verheugt FW; Kakkar AK;
    J Am Coll Cardiol; 2020 Sep; 76(12):1425-1436. PubMed ID: 32943160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Edoxaban treatment in atrial fibrillation in routine clinical care: One-year outcomes of the prospective observational ETNA-AF study in South Korean patients.
    Choi EK; Choi JI; Park HS; Hwang GS; Joung B; Kim JY; Kim DH; Shin DG; Park HW
    J Arrhythm; 2023 Aug; 39(4):546-555. PubMed ID: 37560283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: patient characteristics from the prospective observational ETNA-AF-China registry.
    Guo X; Du J; Yang Y; Wu M; Ou W; Han X; Wang Z; Jin J; Zhang P; Zhang Z; Chen G; Long M; Yin G; Liu T; Wang X; Li D; Chen M; Dong Y; Lai C; Zhang X; Yi Y; Xiang J; Chen C; Unverdorben M; Ma C;
    Sci Rep; 2024 Feb; 14(1):2778. PubMed ID: 38307927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli G; Reiffel J; Singer DE; Peterson ED; Piccini JP;
    J Am Coll Cardiol; 2016 Dec; 68(24):2597-2604. PubMed ID: 27978942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program.
    De Caterina R; Kim YH; Koretsune Y; Wang CC; Yamashita T; Chen C; Reimitz PE; Unverdorben M; Kirchhof P
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33546442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data.
    Monteiro P
    Rev Port Cardiol (Engl Ed); 2020 Nov; 39(11):651-662. PubMed ID: 33190965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study.
    de Groot JR; Weiss TW; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Waltenberger J; Steffel J; Levy P; Bakhai A; Zierhut W; Laeis P; Manu MC; Reimitz PE; De Caterina R; Kirchhof P
    Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f30-f39. PubMed ID: 32790837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
    De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
    BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation.
    Chan YH; Chao TF; Chen SW; Lee HF; Yeh YH; Huang YC; Chang SH; Kuo CT; Lip GYH; Chen SA
    Heart Rhythm; 2020 Dec; 17(12):2102-2110. PubMed ID: 32702416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
    De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation.
    Yu HT; Yang PS; Jang E; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B
    J Am Heart Assoc; 2020 Jun; 9(12):e014177. PubMed ID: 32495677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care.
    Kirchhof P; Pecen L; Bakhai A; de Asmundis C; de Groot JR; Deharo JC; Kelly P; Levy P; Lopez-de-Sa E; Monteiro P; Steffel J; Waltenberger J; Weiss TW; Laeis P; Manu MC; Souza J; De Caterina R
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):47-57. PubMed ID: 35881467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study.
    de Vries TAC; Hemels MEW; Cools F; Crijns HJGM; Yperzeele L; Vanacker P; Blankoff I; Lancellotti P; Mairesse GH; de Veer A; Casado Arroyo R; Catez E; de Pauw M; Vanassche T; de Asmundis C; Kirchhof P; De Caterina R; de Groot JR;
    Acta Cardiol; 2021 Jun; 76(4):431-439. PubMed ID: 33406996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study.
    Russo V; Attena E; Rago A; Melillo E; Di Micco P; Papa AA; Napolitano G; D'Onofrio A; Golino P; Nigro G
    J Clin Med; 2020 May; 9(6):. PubMed ID: 32471222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study.
    de Vries TAC; Hemels MEW; Cools F; Crijns HJGM; Yperzeele L; Vanacker P; Blankoff I; Lancellotti P; Mairesse GH; de Veer A; Casado Arroyo R; Catez E; de Pauw M; Vanassche T; de Asmundis C; Kirchhof P; De Caterina R; de Groot JR;
    Neth Heart J; 2021 Mar; 29(3):158-167. PubMed ID: 33411231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry.
    Gwechenberger M; Barón-Esquivias G; de Vries TAC; Siller-Matula JM; Manu MC; Souza JAG; Wienerroither S; Pecen L; de Groot JR; De Caterina R; Kirchhof P;
    JACC Adv; 2024 Apr; 3(4):100880. PubMed ID: 38939675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing.
    Cho MS; Yun JE; Park JJ; Kim YJ; Lee J; Kim H; Park DW; Nam GB
    Am J Cardiol; 2020 May; 125(9):1332-1338. PubMed ID: 32098658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.